CLINDETS Drug Patent Profile
✉ Email this page to a colleague
When do Clindets patents expire, and when can generic versions of Clindets launch?
Clindets is a drug marketed by Padagis Us and is included in one NDA.
The generic ingredient in CLINDETS is clindamycin phosphate. There are fifty-five drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the clindamycin phosphate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Clindets
A generic version of CLINDETS was approved as clindamycin phosphate by ALMAJECT on July 24th, 1987.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CLINDETS?
- What are the global sales for CLINDETS?
- What is Average Wholesale Price for CLINDETS?
Summary for CLINDETS
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 57 |
| Patent Applications: | 2,341 |
| DailyMed Link: | CLINDETS at DailyMed |
US Patents and Regulatory Information for CLINDETS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Padagis Us | CLINDETS | clindamycin phosphate | SWAB;TOPICAL | 064136-001 | Sep 30, 1996 | AT | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
